SynLaia Innovations, the pioneering company in mechanomics-led drug discovery, is proud to announce its inclusion as a featured case study in the latest report from BioIndustry Association (BIA) - TechBio: Future-Ready Biology (October 2025). This independent publication highlights how the UK's TechBio ecosystem has matured dramatically and underscores SynLaia's role in driving innovation at the intersection of biology, physics and AI. 

The BIA report reveals that TechBio companies - where biology converges with AI and data - now account for over 40% of all UK biotech deals. Between 2020 and 2024, the UK TechBio ecosystem raised in excess of £2.6 billion in capital, including £1.5 billion in venture funding. However, a scale-up gap is still prominent for later-stage investment to sustain growth beyond early-stage proof-of-concept companies.

SynLaia's inclusion in the report demonstrates recognition of its unique approach to integrate mechanomics, tissue modelling and computational platforms to develop unique therapies for novel biological mechanisms, accelerate drug discovery, bridge the gap between biological complexity and predictive analytics. 

“Being featured in the BIA’s TechBio report is a strong validation of our vision. We believe the future of drug discovery lies at the convergence of engineering biology, advanced tissues and deep data. This recognition underlines how far the UK ecosystem has come, and how much further we can go.” said Agata Nyga, CEO and founder of SynLaia.

SynLaia’s case study is set alongside other standout UK companies, illustrating best-in-class practices in tech-enabled bioscience and providing a blueprint for scaling innovation in this emerging sector.